Overview
Justin Fleischacker is an associate in the Litigation Department of Paul Hastings and is based in the firm’s New York office.
His practice focuses on complex patent litigation with an emphasis on pharmaceuticals, medical devices and biotechnology.
Justin received his J.D., cum laude, with a concentration in intellectual property from Benjamin N. Cardozo School of Law in 2018, where he served as an articles editor of the Cardozo Law Review. He earned a Bachelor of Science in Engineering (B.S.E.) in Biomedical Engineering from the University of Connecticut in 2015. Justin is admitted to practice law in New York.
Prior to law school, Justin worked for a leading medical device company and served as a lead inventor on issued patents relating to defibrillator technology for first responders.
Accolades
- Intellectual Property and Life Sciences, Best Lawyers: Ones to Watch in America
- Bench & Bar – Award of Excellence for 2023 Federal Circuit Bar Association Mock Pitch Program, Federal Circuit Bar Association
Representations
- Seagen Inc. v. Daiichi Sankyo Company Limited
- Daiichi Sankyo Company, Limited in a hotly contested complex arbitration and patent dispute worth billions of dollars concerning rights to biotechnology used for its antibody-drug conjugate (ADC) technology. Secured complete victory in a final award that dismissed the opposition’s claims as both substantively meritless and time-barred, and awarded the client $47 million in attorneys’ fees and costs.
- Daiichi Sankyo, Inc. v. Seagen Inc.
- Secured complete victory for Daiichi Sankyo, Inc. at the United States Court of Appeals for the Federal Circuit in a consolidated appeal from a jury trial in the District Court for the Eastern District of Texas and post-grant review proceedings at the U.S. Patent and Trademark Office. Seagen’s antibody-drug conjugate patent was found invalid for failure to meet the written description and enablement requirements, and the jury’s finding of wilful infringement and assessment of damages was vacated.
- Heron Therapeutics v. Fresenius
- Prevailed at trial for Heron Therapeutics relating to a challenge to patents covering Heron’s Cinvanti® treatment for chemotherapy-induced nausea and vomiting.
- Adamas Pharma LLC v. Sandoz
- Secured favorable settlements on behalf of Adamas with first filers in patent infringement actions involving its Gocovri® Parkinson’s medication.
- Eisai Inc. v. Sun Pharmaceutical Industries Ltd.
- Secured favorable settlements on behalf of Eisai and Merck with first filers in patent infringement actions involving their Lenvima® cancer medications.
- Eisai Inc. v. Shilpa Medicare Ltd.
- Prevailed at trial for Eisai and Merck relating to Section 112 challenges to a high-purity patent covering their Lenvima® cancer medications.